***Background.*** Influenza A (H1N1)pdm09 (pH1N1) virus has circulated at different levels during each U.S. influenza season since the 2009 pandemic, with highest levels during the 2013-14 season. A pH1N1 virus (A/California/7/2009) has been included as the H1N1 component of seasonal influenza vaccines since 2010. We investigated effectiveness of seasonal influenza vaccines against medically attended influenza illness due to pH1N1 infection over 3 seasons with varying pH1N1 virus circulation.

***Methods.*** We analyzed data from 9665 patients with medically attended acute respiratory illnesses enrolled at five U.S. Flu VE Network study sites during the 2011-12, 2012-13 and 2013-14 influenza seasons, during periods when pH1N1 virus was identified at ≥1 study site. Respiratory specimens from all enrollees were tested for influenza viruses using reverse transcription PCR. Vaccination was defined as documented or reported receipt of ≥1 dose of current season influenza vaccines at least 14 days before illness onset. Vaccine effectiveness was estimated as 100 x (1 -- adjusted odds ratio) from multivariable logistic regression comparing odds of vaccination among pH1N1-positive cases versus influenza-negative patients.

***Results.*** pH1N1 virus accounted for 112 (25%) of 440 confirmed influenza A virus cases enrolled in 2011-12, 51 (4%) of 1380 cases in 2012-13 and 742 (95%) of 778 cases in 2013-14. Over three seasons, 4401 (50%) of 8760 influenza-negative patients had received ≥1 dose of current season influenza vaccine versus 240 (27%) of 905 pH1N1 cases. After adjusting for season, study site, age, self-reported health status and days from illness onset to enrollment, overall VE against pH1N1 virus infection during three influenza seasons was 65% (95% confidence interval \[CI\]: 59%, 70%), varying from 62% (95% CI: 53%, 69%) in 2013-14 to 81% (95% CI: 61%, 91%) in 2012-13, with no statistically significant difference in VE by season. After combining seasons, adjusted age-group specific VE estimates against pH1N1 ranged from 56% (95% CI:16%, 77%) among patients *≥* 65 years to 79% (95% CI: 54%, 91%) among 9-17 year olds.

***Conclusion.*** The pH1N1 virus included in seasonal influenza vaccines since 2009 provided consistent protection against medically-attended pH1N1 illness 2-4 years after the pandemic despite varying pH1N1 circulation.
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